Demonstrated Safety Profile in MEfRVO

The most common adverse reactions (5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain,
cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.1

VIBRANT, COPERNICUS, and GALILEO:
Most common adverse reactions (≥1%)1

1 / 3
2 / 3
3 / 3
3 / 3

Less common adverse reactions reported in <1% of the patients treated with EYLEA in the
CRVO studies were corneal edema, retinal tear, hypersensitivity, and endophthalmitis.1

Find out more about all
EYLEA indications

Support for the reimbursement process.
Reimbursement Support

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.

Product support for EYLEA® (aflibercept) Injection.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

EYLEA news, events, and more.
Resources

Get the information you
and your patients need
about EYLEA.

Reference
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021